CME: Systemic Sclerosis Interstitial Lung Disease: A Multidisciplinary Approach to Diagnosis & Longitudinal Management

Keys to Diagnosing & Managing Systemic Sclerosis Interstitial Lung Disease

Keys to Diagnosing & Managing Systemic Sclerosis Interstitial Lung Disease

Interstitial lung disease is one of the leading causes of death for patients with systemic sclerosis. How can you catch it early to improve outcomes?

Available credits: 1.00

Time to complete: 60 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Systemic sclerosis (SSc) is a rare chronic disease that involves internal organs and often leads to intestinal, kidney, heart, and lung problems like interstitial lung disease (ILD), which is one of the leading causes of death for these patients. That’s why diagnosing and treating SSc-ILD early is so critical, and this program is designed to help you do just that by identifying risk factors, clinical features, current and emerging therapies, and strategies for taking a multidisciplinary approach to SSc-ILD.

  • Disclosure of Conflicts of Interest

    In accordance with the Accreditation Council for Continuing Medical Education (ACCME), National Jewish Health requires that all program faculty, content developers, CME/CE approval committee, and those in a position to control the content of this activity disclose any relevant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties. All CME/CE educational activities sponsored by National Jewish Health are reviewed to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

    Faculty Presenters
    Mehrnaz Maleki Fischbach, MD has no financial relationships to disclose.
    Maria Padilla, MD discloses that she is on an advisory board for Boehringer Ingelheim, a consultant for Genentech and Takeda as well as a speaker for Genentech and American College of Allergy and Immunology.
    Jesse Roman, MD discloses that he is on a steering committee for Boehringer Ingelheim and conducts research for Galapagos, Genentech and Galecto Biotech.
    Jeffrey Swigris, DO, MS discloses that he is a consultant and receives grant funding for Boehringer Ingelheim and Genenetch as well as a speaker for Genentech.

    Program Planners and Reviewers
    Mandy Comeau has no relevant financial relationships to disclose.
    Stephanie Corder, ND, RN has no relevant financial relationships to disclose.
    Lia R. Matarrese McGibbon, DO has no releveant financial relationships to disclose.
    Amen Sergew, MD has no relevant financial relationships to disclose.

  • Target Audience

    This activity is intended for pulmonologists, rheumatologists and any others who treat patients with SSc-ILD.

  • Learning Objectives

    After completing this activity, the participant should be better able to:

    1. Identify clinical features and risk factors of SSc-ILD based upon best practices for diagnosis.
    2. Apply practice guidelines and clinical evidence related to current and emerging therapies to select treatments for patients with SSc-ILD.
    3. Evaluate strategies for longitudinal management of SSc-ILD using a multidisciplinary approach.
  • Accreditation and Credit Designation Statements

    Accreditation and Designation Statements:
    Physicians: National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    National Jewish Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This collaborative program was developed and presented by National Jewish Health with the Mount Sinai – National Jewish Health Respiratory Institute and the Jane and Leonard Korman Respiratory Institute -  Jefferson Health and National Jewish Health. Together, these three organizations collaborate on research, clinical trials and other programs extending the impact they bring to patients and furthering the understanding of respiratory illness.The Respiratory Institute model of collaboration currently brings these three entities together, collectively referred to as “The Respiratory Institutes”.

    The Respiratory Institutes provide specialized programs committed to multidisciplinary consultation, advanced diagnostics, and coordinated, collaborative care for the full range of lung conditions. With expert faculty working in sync, the Institutes are well-positioned to provide education to health care providers on best practices in respiratory medicine and improving overall care coordination. 

  • Commercial Support

    This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Facebook Comments


We’re glad to see you’re enjoying Rheumatology Academy…
but how about a more personalized experience?

Register for free